Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

talquetamab-tgvs

View Patient Information
A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab-tgvs binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3/anti-GPRC5D bispecific monoclonal antibody JNJ-64407564
GPRC5D x CD3 bispecific antibody JNJ-64407564
GPRC5D x CD3 DuoBody antibody JNJ-64407564
GPRC5D/CD3 DuoBody antibody JNJ-64407564
humanized GPRC5D x CD3 DuoBody antibody JNJ-64407564
talquetamab
US brand name:Talvey
Code name:JNJ 64407564
JNJ-64407564
JNJ64407564
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search